GlassScriptPhysician profile
Robin Reich
NPI 1063218766
$1,077.37
in general payments reported to CMS, 2019-2025
25 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $115.68 | 2025 | Imfinzi |
| Incyte Corporation | $78.57 | 2025 | Monjuvi, Zynyz, Jakafi |
| Beone Medicines USA, INC. | $66.56 | 2025 | Brukinsa, Tevimbra |
| Biosense Webster, INC. | $64.55 | 2025 | Carto 3 |
| Daiichi Sankyo INC. | $59.13 | 2025 | Vanflyta, Datroway, Enhertu |
| Pharmaessentia USA Corporation | $58.08 | 2025 | Besremi |
| Abiomed | $54.68 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.86 | 2025 | Fruzaqla, Iclusig |
| Genzyme Corporation | $50.79 | 2025 | |
| Dendreon Pharmaceuticals LLC | $47.70 | 2025 | Provenge |
| Array Biopharma INC | $47.60 | 2025 | Mektovi, Braftovi, Lorbrena |
| Novartis Pharmaceuticals Corporation | $45.01 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.51 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $44.38 | 2025 | Opdivo |
| Immunocore Limited | $32.82 | 2025 | Kimmtrak |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $29.28 | 2025 | Zoladex |
| Glaxosmithkline, LLC. | $29.15 | 2025 | Ojjaara |
| Agios Pharmaceuticals, INC. | $24.60 | 2025 | Pyrukynd |
| Legend Biotech USA INC. | $23.58 | 2025 | Carvykti |
| Merck Sharp & Dohme LLC | $22.28 | 2025 | Welireg, Keytruda |
| Servier Pharmaceuticals LLC | $19.30 | 2025 | |
| Geron Corporation | $18.39 | 2025 | Rytelo |
| Angiodynamics, INC. | $18.15 | 2025 | Smart Port Ct |
| Recordati_rare_diseases_inc. | $17.70 | 2025 | Enjaymo |
| Boston Scientific Corporation | $14.02 | 2025 | Eluvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Reich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.